window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : April 25, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

CNS disorders

  • Biotech,Central Nervous System,Clinical Development,Drug Development,Rare Diseases,Research & Development

    Lario receives $2.4M from MJFF and Wellcome to expand neuronal calcium channel research in CNS disorders

    Lario Therapeutics awarded $2.4M by The Michael J. Fox Foundation [...]

    February 19, 2026
  • Biotech,Central Nervous System,Clinical Development,Clinical Trials,Pharmaceuticals and therapeutics,Rare Diseases

    Exciva raises €51 million Series B to fund phase 2 Alzheimer’s agitation trial

    Exciva GmbH has raised €51 million ($59m) in a Series [...]

    January 20, 2026
  • Artificial Intelligence,Clinical studies,Digital Health,Medical devices,Neurosciences

    Neuraxpharm and mjn-neuro plan launch of digital solution for early detection of epileptic seizures

    Neuraxpharm and mjn-neuro are preparing to launch a digital health [...]

    December 3, 2025
  • Central Nervous System,Chronic diseases,Drug Delivery & Formulation,European biotech,Pharmaceuticals and therapeutics

    Neuraxpharm launches next-generation oral fumarate Riulvy for multiple sclerosis in Germany

    Neuraxpharm Group has launched Riulvy (tegomil fumarate) in Germany, marking [...]

    October 3, 2025
  • Drug Development,Neurosciences,Rare Diseases,Regulatory Affairs

    SOM Biotech secures EMA orphan designation opinion for Huntington’s drug SOM3355

    Barcelona-based biotech advances Huntington’s programme as EMA backs orphan designation, [...]

    September 15, 2025
  • Central Nervous System,Clinical Trials,Digital Health,Pharmaceuticals and therapeutics

    Investigational schizophrenia digital therapeutic meets key goal in late-stage study

    An investigational prescription digital therapeutic (PDT) designed to treat negative [...]

    August 14, 2025
  • Biologics & Biosimilars,Clinical Development,Drug Development,Market Access & Commercialization,Oncology,Patient Centricity,Regulatory Affairs,Research & Development

    Neuraxpharm expands global reach with launch of Australian affiliate

    Neuraxpharm Group, a leading European specialty pharmaceutical company focused on [...]

    July 22, 2025
  • Drug Development,Precision medicine

    Elkedonia raises EUR 11.25 million to develop new treatment for depression and other neuropsychiatric disorders

    New approach targets Elk1 to restore neuroplasticity without sedation or [...]

    June 12, 2025
  • Clinical Trials,Drug Development

    FTD trial milestone reached as Vesper Bio enrols first asymptomatic GRN carriers

    Vesper Bio has reached a key enrolment milestone in its [...]

    May 12, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Neomorph raises $100 million to advance NEO-811 Phase 1/2 cancer trial and molecular glue degrader pipeline
    Categories: Biotech, Clinical Trials, Drug discovery, Funding, Oncology, Partnerships & Funding, Pharmaceuticals and therapeutics, Research & Development, Technology and platforms
  • NICE expands Lokelma access for hyperkalaemia after draft recommendation
    Categories: Cardiovascular diseases, Chronic diseases, Market Access & Commercialization, Pharmaceuticals and therapeutics, Regulatory Affairs
  • Oncodesign expands ARRONAX deal to secure astatine-211 supply for radiotherapy research
    Categories: CDMOs & Manufacturing, Drug Development, European biotech, Logistics and distribution, Oncology, Partnerships & Funding, Supply Chain & Logistics
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top